{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:23:04Z","timestamp":1760300584749,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basser Global Prize","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Peter Gilgan Centre for Women\u2019s Cancers","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>There is limited information of the outcomes of direct-to-consumer testing for BRCA1 and BRCA2 mutations. The Screen Project was initiated in 2017 to offer BRCA1 and BRCA2 genetic screening to all Canadians over the age of 18 who wish to know their mutation status. Patients enrolled in the study from 2017 to 2019 and were followed for one year after the receipt of a genetic test result. Study subjects registered online and were sent a saliva sample kit, which was shipped to the reference laboratory. Pre-test genetic counselling and counselling for mutation-negative subjects was optional and at the individual\u2019s discretion. There were 1269 tested individuals between March 2017 and January 2019. A total of 1157 (93%) were women and 87 (7%) were men. Sixty-six percent had a first- or second-degree relative with breast or ovarian cancer. Of the 1269 tested individuals, 30 (2.4%) had a pathogenic mutation in BRCA1 or BRCA2 (20 women and 10 men). Seventy-five percent of the female mutation carriers underwent a bilateral mastectomy and\/or salpingo-oophorectomy within a year of receiving a positive result. Genetic counselling was available at no cost to all participants but was requested by only 5% of the non-carriers. The study subjects expressed a high degree of satisfaction with the process.<\/jats:p>","DOI":"10.3390\/cancers13081894","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T12:11:00Z","timestamp":1618488660000},"page":"1894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada"],"prefix":"10.3390","volume":"13","author":[{"given":"Steven A.","family":"Narod","sequence":"first","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Gojska","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Tryon","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"},{"name":"Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON M5T 1P8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad R.","family":"Akbari","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus Guidelines on Genetic\u2019 Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","first-page":"652","article-title":"Faculty Opinions recommendation of Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement","volume":"322","author":"Green","year":"2019","journal-title":"Fac. Opin. Post Publ. Peer Rev. Biomed. Lit."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.2019.8430","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: Updated evidence report and systematic review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.2019.9688","article-title":"Broadening criteria for BRCA1\/2 evaluation: Placing the USPSTF recommendation in context","volume":"322","author":"Domchek","year":"2019","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1910142","DOI":"10.1001\/jamanetworkopen.2019.10142","article-title":"USPSTF recommendations for BRCA1 and BRCA2 testing in the context of a trans-formative National Cancer Control Plan","volume":"2","author":"Rajagopal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamasurg.2019.3184","article-title":"US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer","volume":"154","author":"Newman","year":"2019","journal-title":"JAMA Surg."},{"key":"ref_7","unstructured":"National Comprehensive Cancer Network (2020, August 18). Guidelines for Genetic\/Familial High Risk assessment: Breast and Ovary Version 2 2019. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1503."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-010-1156-9","article-title":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas","volume":"125","author":"Donenberg","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-016-3870-4","article-title":"A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago","volume":"159","author":"Donenberg","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3312-8","article-title":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with tri-ple-negative breast cancer","volume":"150","author":"Weitzel","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award","volume":"312","author":"King","year":"2014","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2017.74.7899","article-title":"Genetic Testing: What Problem Are We Trying to Solve?","volume":"35","author":"Hughes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sie, A.S., Spruijt, L., van Zelst-Stams, W.A., Mensenkamp, A.R., Ligtenberg, M.J., Brunner, H.G., Prins, J.B., and Hoogerbrugge, N. (2012). DNA-testing for BRCA1\/2 prior to genetic counselling in patients with breast cancer: Design of an intervention study, DNA-direct. BMC Womens Health, 12.","DOI":"10.1186\/1472-6874-12-12"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"Un-derdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.18.00025","article-title":"Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking","volume":"4","author":"Ginsburg","year":"2018","journal-title":"J. Glob. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1940-6207.CAPR-09-0218","article-title":"Prevalence of BRCA1 and BRCA2 Mutations in Women with Breast Carcinoma In Situ and Referred for Genetic Testing","volume":"3","author":"Hall","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nombela, P., Lozano, R., Aytes, A., Mateo, J., Olmos, D., and Castro, E. (2019). BRCA2 and Other DDR Genes in Prostate Cancer. Cancers, 11.","DOI":"10.3390\/cancers11030352"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","article-title":"Man-agement of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","volume":"69","author":"Goggins","year":"2020","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4476-1","article-title":"The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy","volume":"167","author":"Giannakeas","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jnci\/djz008","article-title":"Trends in BRCA Test Utilization in an Integrated Health System, 2005\u20132015","volume":"111","author":"Knerr","year":"2019","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:48:13Z","timestamp":1760161693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081894"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081894","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}